Rotenone-Induced Model of Parkinson’s Disease: Beyond Mitochondrial Complex I Inhibition

[1]  R. Cantello,et al.  A very early onset of juvenile parkinsonism , 2022, Journal of Neurology.

[2]  I. Wopara,et al.  Ginkgo biloba protects striatal neurodegeneration and gut phagoinflammatory damage in rotenone-induced mice model of Parkinson's disease: Role of executioner caspase-3/Nrf2/ARE signaling. , 2022, Journal of food biochemistry.

[3]  M. Aschner,et al.  Methylcyclopentadienyl Manganese Tricarbonyl Alter Behavior and Cause Ultrastructural Changes in the Substantia Nigra of Rats: Comparison with Inorganic Manganese Chloride , 2022, Neurochemical Research.

[4]  Souvarish Sarkar,et al.  Environmental Neurotoxic Pesticide Exposure Induces Gut Inflammation and Enteric Neuronal Degeneration by Impairing Enteric Glial Mitochondrial Function in Pesticide Models of Parkinson's Disease: Potential Relevance to Gut-Brain Axis Inflammation in Parkinson's Disease Pathogenesis. , 2022, The international journal of biochemistry & cell biology.

[5]  P. Zamorano,et al.  An Early Disturbance in Serotonergic Neurotransmission Contributes to the Onset of Parkinsonian Phenotypes in Drosophila melanogaster , 2022, Cells.

[6]  C. Tzoulis,et al.  Mitochondrial Respiratory Chain Dysfunction—A Hallmark Pathology of Idiopathic Parkinson’s Disease? , 2022, Frontiers in Cell and Developmental Biology.

[7]  R. Tasker,et al.  Longitudinal Assessment of Behaviour and Associated Bio-Markers Following Chronic Consumption of β-Sitosterol β-D-Glucoside in Rats: A Putative Model of Parkinson’s Disease , 2022, Frontiers in Neuroscience.

[8]  B. Sun,et al.  Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models , 2022, Molecular medicine reports.

[9]  M. Spielmann,et al.  Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state , 2021, Brain : a journal of neurology.

[10]  C. D’Arcy,et al.  Exposure to toxic occupations and their association with Parkinson’s disease: a systematic review with meta-analysis , 2021, Reviews on environmental health.

[11]  S. Haider,et al.  Quercetin exhibits potent antioxidant activity, restores motor and non-motor deficits induced by rotenone toxicity , 2021, PloS one.

[12]  D. Surmeier,et al.  Disruption of mitochondrial complex I induces progressive parkinsonism , 2021, Nature.

[13]  K. Santhakumar,et al.  Chemically induced models of Parkinson's disease. , 2021, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[14]  Y. Sharabi,et al.  Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP , 2021, Journal of Molecular Neuroscience.

[15]  M. Hickey,et al.  Using Rotenone to Model Parkinson's Disease in Mice: A Review of the Role of Pharmacokinetics. , 2021, Chemical research in toxicology.

[16]  L. Sheppard,et al.  Severity of parkinsonism associated with environmental manganese exposure , 2021, Environmental Health.

[17]  Hsin-Yi Lai,et al.  The Association Between the Gut Microbiota and Parkinson's Disease, a Meta-Analysis , 2021, Frontiers in Aging Neuroscience.

[18]  Inah Kim,et al.  Parkinson's disease in a worker exposed to insecticides at a greenhouse , 2021, Annals of occupational and environmental medicine.

[19]  Liyan Hou,et al.  Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson’s disease model , 2020, Journal of neuroinflammation.

[20]  Steven McKnight,et al.  Toxin-Induced Parkinsonism. , 2020, Neurologic clinics.

[21]  M. Xie,et al.  Bisdemethoxycurcumin exerts a cell-protective effect via JAK2/STAT3 signaling in a rotenone-induced Parkinson's disease model in vitro. , 2020, Folia histochemica et cytobiologica.

[22]  A. Çağaç.  Farming, well water consumption, rural living, and pesticide exposure in early life as the risk factors for Parkinson disease in Iğdır province , 2020, Neurosciences.

[23]  E. Tan,et al.  Historical Perspective: Models of Parkinson’s Disease , 2020, International journal of molecular sciences.

[24]  G. Tanriover,et al.  Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation , 2020, Pharmacological Reports.

[25]  K. Shannon,et al.  Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease , 2020, Neurobiology of Disease.

[26]  M. Schaalan,et al.  Neuroprotective effect of crocin against rotenone-induced Parkinson's disease in rats: Interplay between PI3K/Akt/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221 , 2019, Neuropharmacology.

[27]  K. Ye,et al.  Initiation of Parkinson’s disease from gut to brain by δ-secretase , 2019, Cell Research.

[28]  J. Jankovic,et al.  Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. , 2019, Parkinsonism & related disorders.

[29]  K. Blennow,et al.  Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease , 2019, Alzheimer's Research & Therapy.

[30]  R. El Dib,et al.  Paraquat and Parkinson’s disease: a systematic review and meta-analysis of observational studies , 2019, Journal of toxicology and environmental health. Part B, Critical reviews.

[31]  N. Bray.  The microbiota–gut–brain axis , 2019 .

[32]  G. Koren,et al.  Chronic Use of β-Blockers and the Risk of Parkinson’s Disease , 2019, Clinical Drug Investigation.

[33]  Janez Mavri,et al.  Dopamine Autoxidation Is Controlled by Acidic pH , 2018, Front. Mol. Neurosci..

[34]  H. Wiendl,et al.  Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease , 2018, Front. Neurol..

[35]  J. Pedraza-Chaverri,et al.  Docosahexaenoic acid protection in a rotenone induced Parkinson's model: Prevention of tubulin and synaptophysin loss, but no association with mitochondrial function , 2018, Neurochemistry International.

[36]  U. Rajendra Acharya,et al.  Parkinson's disease: Cause factors, measurable indicators, and early diagnosis , 2018, Comput. Biol. Medicine.

[37]  Liegang Liu,et al.  Pesticide exposure and risk of Parkinson's disease: Dose‐response meta‐analysis of observational studies , 2018, Regulatory toxicology and pharmacology : RTP.

[38]  Mingyan Liu,et al.  Association of circulating manganese levels with Parkinson’s disease: A meta-analysis , 2018, Neuroscience Letters.

[39]  M. Zeviani,et al.  Neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage , 2018, Acta Neuropathologica.

[40]  M. Hallett,et al.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[41]  Vladimir Gelfand,et al.  Microtubule-Based Transport and the Distribution, Tethering, and Organization of Organelles. , 2017, Cold Spring Harbor perspectives in biology.

[42]  J. Langston,et al.  The MPTP Story , 2017, Journal of Parkinson's disease.

[43]  Fen Wang,et al.  Parkinson’s disease‐like motor and non‐motor symptoms in rotenone‐treated zebrafish , 2017, Neurotoxicology.

[44]  A. Rodriguez-Perez,et al.  Menopause and Parkinson’s disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration , 2016, Frontiers in Neuroendocrinology.

[45]  Mark R Cookson,et al.  Genes associated with Parkinson's disease: regulation of autophagy and beyond , 2016, Journal of neurochemistry.

[46]  L. Bubacco,et al.  α-Synuclein is a Novel Microtubule Dynamase , 2016, Scientific Reports.

[47]  F. N. Emamzadeh.  Alpha-synuclein structure, functions, and interactions , 2016, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[48]  N. Jetté,et al.  The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis , 2016, Neuroepidemiology.

[49]  Andrew J Schwab,et al.  Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson’s Disease-Related LRRK2 G2019S Mutation , 2015, Stem cell reports.

[50]  Suneil K. Kalia,et al.  Disease‐modifying strategies for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[51]  D. Geschwind,et al.  Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism , 2015, Proceedings of the National Academy of Sciences.

[52]  S. Cragg,et al.  Impaired intracellular trafficking defines early Parkinson's disease , 2015, Trends in Neurosciences.

[53]  S. Ge,et al.  Parkin Mutations Reduce the Complexity of Neuronal Processes in iPSC‐Derived Human Neurons , 2015, Stem cells.

[54]  J. Blesa,et al.  Parkinson’s disease: animal models and dopaminergic cell vulnerability , 2014, Front. Neuroanat..

[55]  W. Banks,et al.  Alpha synuclein is transported into and out of the brain by the blood–brain barrier , 2014, Peptides.

[56]  A. Whitworth,et al.  Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations , 2014, Nature Communications.

[57]  T. Südhof,et al.  α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation , 2014, Proceedings of the National Academy of Sciences.

[58]  V. Uversky,et al.  Biophysical Characterization of α-Synuclein and Rotenone Interaction , 2013, Biomolecules.

[59]  R. Riek,et al.  α-Synuclein Oligomers Impair Neuronal Microtubule-Kinesin Interplay* , 2013, The Journal of Biological Chemistry.

[60]  A. Schapira,et al.  Somatic Alpha-Synuclein Mutations in Parkinson's Disease: Hypothesis and Preliminary Data , 2013, Movement disorders : official journal of the Movement Disorder Society.

[61]  D. Passarella,et al.  Microtubule Alterations Occur Early in Experimental Parkinsonism and The Microtubule Stabilizer Epothilone D Is Neuroprotective , 2013, Scientific Reports.

[62]  J. Paul Bolam,et al.  The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease , 2013, Front. Comput. Neurosci..

[63]  C. Torner,et al.  Efecto de la exposición al pesticida rotenona sobre el desarrollo del sistema dopaminérgico nigro-estriatal en ratas , 2013 .

[64]  D. Perani,et al.  In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. , 2013, Parkinsonism & related disorders.

[65]  F. Micheli,et al.  Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms , 2013, Journal of Neurology.

[66]  A. Lees,et al.  Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease , 2012, Annals of neurology.

[67]  M. Avila-Costa,et al.  Manganese mixture inhalation is a reliable Parkinson disease model in rats. , 2012, Neurotoxicology.

[68]  A. Winslow,et al.  Exosomal cell-to-cell transmission of alpha synuclein oligomers , 2012, Molecular Neurodegeneration.

[69]  A. Mahadevan,et al.  Increased Oxidative Damage and Decreased Antioxidant Function in Aging Human Substantia Nigra Compared to Striatum: Implications for Parkinson’s Disease , 2012, Neurochemical Research.

[70]  Wei Wang,et al.  A soluble α-synuclein construct forms a dynamic tetramer , 2011, Proceedings of the National Academy of Sciences.

[71]  D. Selkoe,et al.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.

[72]  H. Adami,et al.  Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.

[73]  R. Palmiter,et al.  Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model , 2011, The Journal of cell biology.

[74]  J. Lemasters,et al.  Free tubulin modulates mitochondrial membrane potential in cancer cells. , 2010, Cancer research.

[75]  K. Lyons,et al.  Mitochondrial respiration and respiration‐associated proteins in cell lines created through Parkinson’s subject mitochondrial transfer , 2010, Journal of neurochemistry.

[76]  R. Swerdlow,et al.  Microtubule Depolymerization Potentiates Alpha-Synuclein Oligomerization , 2009, Front. Ag. Neurosci..

[77]  H. Lashuel,et al.  Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. , 2010, Progress in brain research.

[78]  K. Fountas,et al.  Genetic basis of Parkinson disease. , 2010, Neurosurgical focus.

[79]  Organización Mundial de la Salud.  The WHO recommended classification of pesticides by hazard and guidelines to classification 2009 , 2010 .

[80]  Y. Jing,et al.  Molecular interaction of α-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells , 2010, Molecular Biology Reports.

[81]  Carola Seifried,et al.  Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. , 2009, Brain : a journal of neurology.

[82]  Victor Tapias,et al.  A highly reproducible rotenone model of Parkinson's disease , 2009, Neurobiology of Disease.

[83]  R. Swerdlow,et al.  Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids. , 2009, Antioxidants & redox signaling.

[84]  Amany A. Abdin,et al.  Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism , 2008, Neuropharmacology.

[85]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[86]  R. Palmiter,et al.  Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat , 2008, Proceedings of the National Academy of Sciences.

[87]  A. Stępień,et al.  Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism , 2008, Neuroscience Letters.

[88]  Y. Itoyama,et al.  Serine 129 Phosphorylation of α-Synuclein Induces Unfolded Protein Response-mediated Cell Death* , 2008, Journal of Biological Chemistry.

[89]  J. Levin,et al.  Pesticide/Environmental Exposures and Parkinson's Disease in East Texas , 2008, Journal of agromedicine.

[90]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[91]  A. C. Belin,et al.  Parkinson’s disease: A genetic perspective , 2008, The FEBS journal.

[92]  K. Kiuchi,et al.  The role of dopamine transporter in selective toxicity of manganese and rotenone. , 2008, Toxicology.

[93]  S. Das,et al.  Parkin polymorphisms: risk for Parkinson’s disease in Indian population , 2007, Clinical genetics.

[94]  Shu G. Chen,et al.  The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. , 2007, Experimental cell research.

[95]  D. Panda,et al.  Rotenone inhibits mammalian cell proliferation by inhibiting microtubule assembly through tubulin binding , 2007, The FEBS journal.

[96]  Makoto Hashimoto,et al.  Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. , 2007, Biochemical and biophysical research communications.

[97]  J. Olzmann,et al.  PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1 , 2007, PLoS biology.

[98]  Michael Aschner,et al.  Manganese neurotoxicity: a focus on the neonate. , 2007, Pharmacology & therapeutics.

[99]  D. Thurman,et al.  How common are the “common” neurologic disorders? , 2007, Neurology.

[100]  K. Lim,et al.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.

[101]  A. Abeliovich,et al.  The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.

[102]  J. Nutt,et al.  LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. , 2006, American journal of human genetics.

[103]  Á. Hermida-Ameijeiras,et al.  Study on the ability of 1,2,3,4‐tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to parkinson's disease , 2006, Journal of biochemical and molecular toxicology.

[104]  A. Doig,et al.  A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. , 2006, Biochemistry.

[105]  J. Molinuevo,et al.  Genética de las enfermedades neurodegenerativas más prevalentes , 2006 .

[106]  Robert W. Taylor,et al.  High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.

[107]  H. Braak,et al.  Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.

[108]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[109]  M. Youdim,et al.  M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[110]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[111]  I. Miyazaki,et al.  Rotenone induces aggregation of γ-tubulin protein and subsequent disorganization of the centrosome: Relevance to formation of inclusion bodies and neurodegeneration , 2005, Neuroscience.

[112]  Wenhua Liu,et al.  Selective Vulnerability of Dopaminergic Neurons to Microtubule Depolymerization* , 2005, Journal of Biological Chemistry.

[113]  M. Farrer,et al.  Lrrk2 pathogenic substitutions in Parkinson's disease , 2005, Neurogenetics.

[114]  P. Narongchai,et al.  The first fatal case of yam bean and rotenone toxicity in Thailand. , 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[115]  Jian Feng,et al.  Parkin Stabilizes Microtubules through Strong Binding Mediated by Three Independent Domains* , 2005, Journal of Biological Chemistry.

[116]  P. Dargan,et al.  Fatality after deliberate ingestion of the pesticide rotenone: a case report , 2005, Critical care.

[117]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[118]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[119]  T. Sherer,et al.  Rotenone Model of Parkinson’s Disease: Multiple Brain Mitochondria Dysfunctions after Short-term Systemic Rotenone Intoxication , 2005 .

[120]  S. Birman,et al.  Chronic Exposure to Rotenone Models Sporadic Parkinson's Disease in Drosophila melanogaster , 2004, The Journal of Neuroscience.

[121]  M. Vila,et al.  MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease , 2004, Journal of bioenergetics and biomembranes.

[122]  Mark A. Wilson,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[123]  Cheryl D. DiCarlo,et al.  Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone , 2004, Experimental Neurology.

[124]  Werner J. Schmidt,et al.  Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain , 2004, Experimental Neurology.

[125]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[126]  Marisol López,et al.  Factores genéticos involucrados en la susceptibilidad para desarrollar enfermedad de Parkinson , 2004 .

[127]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[128]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[129]  Jean Féger,et al.  Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.

[130]  Jian Feng,et al.  Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[131]  D. Sulzer,et al.  The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. , 2003, Journal of neural transmission. Supplementum.

[132]  W. Schmidt,et al.  Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats , 2002, Behavioural Brain Research.

[133]  Hansjürgen Bratzke,et al.  Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) , 2002, Journal of Neurology.

[134]  V. Uversky.  Cracking the folding code. Why do some proteins adopt partially folded conformations, whereas other don't? , 2002, FEBS letters.

[135]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[136]  G. Gerhardt,et al.  Changes in somatodendritic but not terminal dopamine
regulation in aged rhesus monkeys , 2002, Journal of neurochemistry.

[137]  K. Arima,et al.  Tubulin seeds alpha-synuclein fibril formation. , 2002, The Journal of biological chemistry.

[138]  J. George,et al.  The synucleins , 2001, Genome Biology.

[139]  G. Petzinger,et al.  The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.

[140]  G. Bedoya,et al.  A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia , 2001, Neuroscience Letters.

[141]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[142]  J. Langston,et al.  Increased striatal dopamine turnover following acute administration of rotenone to mice , 2000, Brain Research.

[143]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[144]  M. Polymeropoulos,et al.  Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients , 2000, Neuroreport.

[145]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[146]  H. Ichinose,et al.  Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain , 2000, Journal of Neural Transmission.

[147]  J. Casida,et al.  Cubé resin insecticide: identification and biological activity of 29 rotenoid constituents. , 1999, Journal of agricultural and food chemistry.

[148]  D B Calne,et al.  Manganese neurotoxicity: a review of clinical features, imaging and pathology. , 1999, Neurotoxicology.

[149]  K. Herholz,et al.  Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure , 1999, Journal of Neurology.

[150]  G. Dryhurst,et al.  Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. , 1998, Chemical research in toxicology.

[151]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[152]  E. Floor,et al.  Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.

[153]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[154]  J. Schulz,et al.  Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.

[155]  M. Polymeropoulos,et al.  Linkage of the locus for cerebral cavernous hemangiomas to human chromosome 7q in four families of Mexican-American descent , 1997, Neurology.

[156]  M. Polymeropoulos,et al.  Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.

[157]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[158]  D. Law-Tho,et al.  Dopamine modulation of synaptic transmission in rat prefrontal cortex: an in vitro electrophysiological study , 1994, Neuroscience Research.

[159]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[160]  C. Hertzman,et al.  A case‐control study of Parkinson's disease in a horticultural region of British Columbia , 1994, Movement disorders : official journal of the Movement Disorder Society.

[161]  J. Nutt,et al.  Environmental antecedents of young‐onset Parkinson's disease , 1993, Neurology.

[162]  H. Przuntek,et al.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. , 1991, European journal of pharmacology.

[163]  C. Hertzman,et al.  Parkinson's disease: a case-control study of occupational and environmental risk factors. , 1990, American journal of industrial medicine.

[164]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[165]  L. Hartwell,et al.  Dominant effects of tubulin overexpression in Saccharomyces cerevisiae , 1989, Molecular and cellular biology.

[166]  S. Harik,et al.  Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier. , 1988, Life sciences.

[167]  G. Campanella,et al.  Ecogenetics of Parkinson's Disease: Prevalence and Environmental Aspects in Rural Areas , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[168]  J. Luthman,et al.  Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice. , 1986, Acta physiologica Scandinavica.

[169]  A. Heyndrickx,et al.  A case of fatal rotenone poisoning in a child. , 1986, Journal of forensic sciences.

[170]  R. Duvoisin,et al.  Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.

[171]  M. da Prada,et al.  Evidence for the release of 1-methyl-4-phenylpyridinium (MPP+) from rat striatal neurons in vitro. , 1985, European journal of pharmacology.

[172]  R. Himes,et al.  Rotenone inhibition of tubulin self-assembly. , 1978, Biochimica et biophysica acta.

[173]  E. A. Holland.  Suicide by ingestion of derris root sp, in New Ireland , 1938 .

[174]  H. Haller,et al.  The Determination of the Structure of Rotenone. , 1933 .